INTRAVENOUS SOLUTIONS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Global intravenous solutions market is estimated to be valued at USD 11.77 Bn in 2026 and is expected to exhibit a CAGR of 6.5% during the forecast period (2026-2033). Intravenous solutions (IV) are administered in patients to provide sugar, salt and water directly into venous circulation. IV solutions and electrolytes are used for fluid resuscitation, routine maintenance, replacement, and redistribution. Nowadays, intravenous drugs, nutrition and mixed solutions have become an integral part of modern therapy. The intravenous route of administration is commonly used for rehydration or to provide nutrients for those who cannot, or will not, due to reduced mental states or otherwise, consume food or water by mouth. It may also be used to administer medications or other medical therapy such as blood products or electrolytes to correct electrolyte imbalances.

Figure 1. Global Intravenous Solutions Market Value (US$ Bn), by Region, 2026

Increasing launches and regulatory approvals for intravenous solution injection is expected to drive growth of the global intravenous solution market

Market players are involved in launching new intravenous injection solutions which is expected to boost the growth of global intravenous solutions market over the forecast period. For instance, in September 2021, Baxter International Inc., a global sterile medication production company, announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine). Norepinephrine is indicated to raise blood pressure in adult patients with severe, acute hypotension (low blood pressure). Baxter’s formulation of norepinephrine is the first and only manufacturer-prepared ready-to-use formulation and is available in 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL) strengths.

Figure 2. Global Intravenous Solutions Market Share, By Solution, 2026

Increasing launches of parenteral (intravenous) nutrition (PN) products by key market players is attributing to the highest share of North America market in the global intravenous solutions market.

Increasing launches of parenteral (intravenous) nutrition (PN) products by key players in market for developing global intravenous solutions is expected to drive market growth over the forecast period. For instance, in June 2019, Eurolife Healthcare, a manufacturer and distributor of specialty infusion & pharmaceuticals, launched two intravenous IV products: Discport and Lifeport in the India drug market. The product is considered as smart intravenous infusion, which encompasses the latest technology that reduces the chances of any infection.

In addition to this, a significant growth-inducing element is the rise in diabetes, cancer, gastrointestinal problems, and neurological illnesses. Additionally, IV solution therapy's superior efficacy and quicker response time are fostering market expansion. It is employed to treat chronic dehydration, a disease that can lead to weariness, memory loss, irritability, and other health issues. For instance, in February 2022, the World Health Organization published a report which stated that nearly 10 million deaths in 2020, or nearly one in six deaths globally due to cancer. Cancer-causing infections, such as human papillomavirus (HPV) and hepatitis, are responsible for approximately 30% of cancer cases in low- and lower-middle-income countries like India and Bangladesh.

Recent Developments

• In October 2023, Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved an intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of adults suffering from psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). Cosentyx is the only authorized IV formulation that targets and inhibits interleukin-17A (IL-17A), as well as the only non-tumor necrosis factor alpha (TNF-α) IV option accessible in all indications.
• In February 2023, The U.S. FDA approved ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], formerly known as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement treatment. ALTUVIIIO is recommended for regular prophylaxis and on-demand therapy to reduce bleeding episodes, as well as perioperative care (surgery) in adults and children with hemophilia A.
• In June 2022, Breckenridge Pharmaceutical, Inc., a generic pharmaceutical manufacturing company, announced that the U.S. Food and Drug Administration (FDA) had granted approval for its Abbreviated New Drug Application for Cabazitaxel Intravenous Powder. This product was developed in collaboration with Natco Pharma Limited, a multinational pharmaceutical company.  Breckenridge received final approval for the 60mg/1.5mL (40mg/mL) strength.
• In May 2022, SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on the health security market, announced that the U.S. FDA had approved an intravenous (IV) version of TPOXX for the treatment of smallpox. The IV formulation is a significant option for patients who are unable to take TPOXX's oral capsules.
• In July 2021, Grifols, a prominent  global supplier of plasma-derived pharmaceuticals, announced that it would establish an intravenous (IV) solutions manufacturing facility in Nigeria for Dozie and Dozie's Pharma Nig Ltd., a leading distributor of healthcare products in the Nigeria and surrounding regions. When finished in southeast Nigeria in 2025, the manufacturing installation's initial phase will produce up to 5.5 million intravenous solution bags per year for use in Nigerian and other African hospitals and healthcare facilities.
• In December 2020, Royal Philips, a health technology company, announced that it had signed an agreement to acquire Vesper Medical Inc., a U.S.-based medical technology company that develops minimally-invasive peripheral vascular devices. Vesper Medical will further expand Philips portfolio of diagnostic and therapeutic devices with an advanced venous stent portfolio for the treatment of deep venous disease. 

Intravenous Solutions Market Restraints

Growth of the global intravenous solution market is expected to be hampered over the forecast period, owing to increasing FDA recalls of IV products. For instance, in August 2018, the U.S. FDA recalled Becton Dickinson & Company’s NEXIVA Closed IV Catheter System Dual Port 18GA 1.25 IN (BD Nexiva catheter) due to failure in the needle tip shield/safety mechanism.

Key Players

Key players operating in the global intravenous solutions market include Baxter International Inc., ICU Medical. Inc, B. Braun Melsungen Ag, Grifols, S.A., Fresenius Kabi USA, LLC, Vifor Pharma Management Ltd, JW Life Science, Amanta Healthcare, Axa Parenterals Ltd, and Salius Pharma Private Limited, Pfizer, Inc, Otsuka Pharmaceutical Co., Ltd, Ajinomoto Co., Inc., B. Braun Melsungen AG, Soxa Formulations & Research Pvt.Ltd, Sichuan Kelun Pharmaceutical Co Ltd.